Indication
Primary
17 clinical trials
26 products
1 drug
Clinical trial
A Phase 1/2 Study of PBI-200 in Subjects With NTRK-Fusion-Positive Advanced or Metastatic Solid TumorsStatus: Terminated, Estimated PCD: 2023-07-26
Product
PBI-200Clinical trial
A TWO-PART, PHASE 1A/B, OPEN-LABEL, MULTICENTER TRIAL EVALUATING PHARMACOKINETICS, SAFETY AND EFFICACY OF PF 07284890 (ARRY 461) IN PARTICIPANTS WITH BRAF V600 MUTANT SOLID TUMORS WITH AND WITHOUT BRAIN INVOLVEMENTStatus: Terminated, Estimated PCD: 2024-03-20
Product
MidazolamProduct
PF-07284890Product
BinimetinibClinical trial
Parametric Cardiac 18F-flutemetamol PET Imaging in ATTR CardiomyopathyStatus: Recruiting, Estimated PCD: 2025-06-01
Product
(18F)FlutemetamolClinical trial
Patients With IDH1 Positive Recurrent Grade II Glioma Enrolled in a Safety and Immunogenicity Study of Tumor-Specific Peptide VaccineStatus: Completed, Estimated PCD: 2020-02-03
Product
PEPIDH1MProduct
Tetanus-Diphtheria ToxoidProduct
TMZClinical trial
The AUDYT Trial: An Open-label Study to Define the Safety, Tolerability and Clinical Activity of Deutetrabenazine (AUstedo) in Adult Study Subjects With DYsToniaStatus: Active (not recruiting), Estimated PCD: 2024-03-01
Product
DeutetrabenazineClinical trial
LOC-R01: Randomized Phase IB/II Study of Escalating Doses of Lenalidomide and Ibrutinib in Association With R-MPV as a Targeted Induction Treatment for Patients Aged 18 to 60 (up to 65 for Phase II) With a Newly Diagnosed Primary Central Nervous System LymphomaStatus: Recruiting, Estimated PCD: 2024-01-15
Product
LenalidomideProduct
IbrutinibClinical trial
Performance of Elucirem® (Gadopiclenol) in Dynamic Susceptibility Contrast Magnetic Resonance Imaging (DSC-MRI) Perfusion of Brain Gliomas Phase IIIb Clinical TrialStatus: Recruiting, Estimated PCD: 2024-04-29
Product
EluciremProduct
DotaremClinical trial
Phase I/II Study of Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed Glioblastoma (GBM)Status: Recruiting, Estimated PCD: 2026-06-01
Product
CapecitabineClinical trial
Efficacy of Erenumab in Chronic Cluster Headache: A 10 Week Double-blind, Randomized, Placebo Controlled, Multicentric Trial.Status: Completed, Estimated PCD: 2023-09-27
Product
ErenumabProduct
PlaceboClinical trial
18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid AdenomasStatus: Recruiting, Estimated PCD: 2026-06-30
Product
18F-FluorocholineClinical trial
A Clinical Approach to Validate the Biological Significance of LPC16:0 as a Discriminating and Pathogenic Biomarker of FibromyalgiaStatus: Recruiting, Estimated PCD: 2025-07-31
Product
PregabalinClinical trial
Cognitive Behavioral Therapy and Trazodone Effects on Sleep and Blood Pressure in Insomnia Phenotypes Based on Objective Sleep Duration: A Sequential Cohort/Randomized Controlled TrialStatus: Recruiting, Estimated PCD: 2027-02-01
Product
TrazodoneClinical trial
Intramuscular Paracervical Injection for Headache in the Emergency Department: A Randomized Controlled TrialStatus: Active (not recruiting), Estimated PCD: 2023-09-15
Product
ParacervicalClinical trial
Psilocybin-facilitated Treatment for Chronic PainStatus: Recruiting, Estimated PCD: 2024-12-01
Product
PsilocybinProduct
DextromethorphanClinical trial
Phase 1 Trial of Engineered HSV G207 in Children With Recurrent or Refractory Cerebellar Brain TumorsStatus: Active (not recruiting), Estimated PCD: 2025-09-01
Product
G207Clinical trial
The Impact of THC on Pain Modulation in Fibromyalgia: A Cross-Over, Randomized, Double-Blind Placebo-Controlled StudyStatus: Recruiting, Estimated PCD: 2024-04-01
Product
THCDrug
VarlilumabClinical trial
Spironolactone Therapy in Chronic Stable Right HF TrialStatus: Completed, Estimated PCD: 2022-08-30
Product
Spironolactone